Trial Profile
A Single-arm Phase II Multicenter Study of IDH2 (AG-221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Jan 2023
Price :
$35
*
At a glance
- Drugs Enasidenib (Primary) ; Azacitidine
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- Acronyms GFM-IDEAL-Study
- 14 Dec 2021 Interim Results (At data cut off 6/15/2021, n=26)presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 12 Nov 2020 Planned primary completion date changed from 18 Feb 2021 to 18 Feb 2023.
- 06 Nov 2020 Planned End Date changed from 12 Jan 2023 to 18 Feb 2023.